France · Delayed Price · Currency is EUR Innate Pharma Company Description
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells.
It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.
In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor.
The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech.
Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.
| Country | France |
| Founded | 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 174 |
| CEO | Jonathan Dickinson |
Contact Details
Address: 117, Avenue de Luminy Marseille, 13009 France | |
| Phone | 33 4 30 30 30 30 |
| Website | innate-pharma.com |
Stock Details
| Ticker Symbol | IPH |
| Exchange | Euronext Paris |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | FR0010331421 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jonathan E. Dickinson B.Sc., M.B.A. | Chief Executive Officer and Director |
| Yannis Morel Ph.D. | Executive Vice President and Chief Operating Officer |
| Dr. Sonia Quaratino M.D., Ph.D. | Executive Vice President and Chief Medical Officer |
| Dr. François Romagné Ph.D. | Founder |
| Dr. Marc Bonneville Ph.D. | Founder |
| Jean Jacques Fournié Ph.D. | Founder |
| Alessandro Moretta M.D., Ph.D. | Founder |
| Frederic Lombard M.B.A. | Senior Vice President and Chief Financial Officer |
| Stephanie Cornen | Vice President of Investor Relations, Communication and Commercial Strategy |
| Odile Belzunce | Vice President, Chief of Compliance and Operations Officer and Interim Head of Human Resources |